The strain in opposition to pharmacy profit managers (PBMs) continues to construct.
On Tuesday, the Federal Commerce Fee (FTC) launched its second interim employees report on prescription drug middlemen. The report examines the influence of PBMs (particularly CVS Caremark, Categorical Scripts and Optum Rx) on specialty generic medicine, highlighting substantial value markups by PBMs on drugs for most cancers, HIV and different circumstances. The fee voted 5-0 to launch the report.
“The FTC employees’s second interim report finds that the three main pharmacy profit managers hiked prices for a variety of lifesaving medicine, together with drugs to deal with coronary heart illness and most cancers,” mentioned FTC Chair Lina M. Khan in an announcement. “The FTC ought to maintain utilizing its instruments to research practices that will inflate drug prices, squeeze unbiased pharmacies, and deprive Individuals of reasonably priced, accessible healthcare—and will act swiftly to cease any unlawful conduct.”
The brand new report is the most recent growth in a battle that has been brewing between the FTC and the PBMs. The company launched its first interim employees report on PBMs in July, which detailed how concentrated the PBM market has develop into. As well as, the FTC sued CVS Caremark, Categorical Scripts and Optum Rx over insulin costs in September, prompting the Huge Three PBMs to countersue the company in November, claiming the company’s lawsuit is unconstitutional.
Whereas a number of healthcare executives are popping out in assist of the report, the PBMs named within the report are unsurprisingly decrying its findings.
What the FTC discovered
Within the second interim report, the FTC examined specialty generic medicine disbursed between 2017 and 2022 for members of economic well being plans and Medicare Half D prescription drug plans managed by the Huge Three PBMs. This differs from the earlier report, which analyzed two specialty generic medicine.
The FTC discovered that the highest three PBMs utilized markups starting from lots of to 1000’s of % on varied specialty generic medicine disbursed by their affiliated pharmacies, together with drugs for most cancers and HIV. The PBMs additionally reimbursed their affiliated pharmacies at larger charges than they paid to unaffiliated pharmacies for practically each specialty generic drug reviewed.
Through the examine interval, the affiliated pharmacies of the Huge Three PBMs earned greater than $7.3 billion in dishing out income above their estimated acquisition value, as decided by the Nationwide Common Drug Acquisition Value (NADAC), on specialty generic medicine, the FTC additionally reported.
As well as, the three PBMs earned about $1.4 billion of revenue from unfold pricing on the specialty generic medicine analyzed within the report in the course of the examine interval. Unfold pricing is when PBMs invoice their plan sponsor shoppers greater than what they reimburse pharmacies for prescribed drugs.
“These outcomes illustrate the growing monetary significance of specialty generic medicine to the Huge 3 PBMs, in addition to to plan sponsors and sufferers,” the FTC said within the report. “The outcomes additionally reveal that the 2 case examine medicine analyzed in our First Interim Workers Report weren’t remoted examples. This report confirms that the Huge 3 PBMs impose important markups on a big selection of specialty generic medicine.”
The response
The Huge Three PBMs have largely criticized the FTC report.
A spokesperson for CVS Well being argued that the FTC has drawn broad conclusions from “cherry-picked” specialty generic outliers in each of its interim stories.
“Between 2017-2022, specialty generic merchandise have represented lower than 1.5% of our shoppers’ complete drug spend and solely 51 out of 1000’s of medicine,” mentioned David Whitrap, vp of exterior affairs at CVS Well being, in an e-mail. “In distinction, branded specialty merchandise characterize greater than 50% of our shoppers’ complete drug spend and are fully ignored by the FTC.”
Categorical Scripts, in the meantime, declared in an announcement that “nothing within the FTC’s report addresses the underlying trigger of accelerating drug costs, or helps employers, unions, and municipalities maintain prescription advantages reasonably priced for his or her members.”
An Optum spokesperson informed MedCity Information that the corporate continues to be reviewing the report, however pointed to work it’s doing to lower drug costs.
“Optum is reducing the price of specialty drugs, which includes half of all drug expenditures, and offering scientific experience, packages and assist for sufferers with complicated and uncommon circumstances,” the spokesperson mentioned. “In 2024, we helped eligible sufferers save $1.3 billion and the median out-of-pocket fee for these sufferers was $5.”
Whereas the PBMs are strongly criticizing the findings of the report, one trade professional — Antonio Ciaccia, CEO of 46booklyn — mentioned he’s glad to not be the one one working to show PBM practices. He mentioned he launched 46brooklyn in 2018 with an exposé on how Medicaid packages have been being overcharged for generic Gleevec, one of many medicine talked about within the report.
“We have been informed by PBMs that our deal with this drug was an train in cherry choosing. Since then, we have now recognized a litany of different examples of those exorbitant markups on generic specialty medicine and the way PBM conflicts of curiosity within the specialty pharmacy market have resulted in extreme expenses to employers, Medicare, and sufferers,” he mentioned. “I’d like to say I’m shocked by the findings, however I’m not. I’m simply pleased to not really feel like I’m alone in figuring out these unlucky realities.”
Ellen Rudolph, CEO of autoimmune digital well being firm WellTheory, famous that the FTC’s findings “underscore a essential challenge in our healthcare system: the numerous markups on specialty medicine not solely pressure sufferers but additionally create substantial monetary burdens for employers.”
One other healthcare government known as on policymakers to step up primarily based on the findings of the report.
“Sufferers can be nicely served if these so-called specialty medicine have been capable of be disbursed by their most popular group pharmacy,” mentioned Douglas Hoey, CEO of the Nationwide Group Pharmacists Affiliation. “As an alternative, nonetheless, for the PBMs’ monetary achieve, sufferers’ alternative is oftentimes restricted to PBM-owned mail-order pharmacies and their care is sadly disrupted. That is simply the most recent apparent sign to policymakers that they have to go PBM reform that would come with paying for prescriptions primarily based on the price of the drug plus a clear pharmacist skilled dishing out charge.”
Photograph: z_wei, Getty Photos